Literature DB >> 11907170

Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.

Hsia-lien Lin1, Ute M Kent, Paul F Hollenberg.   

Abstract

17 alpha-Ethynylestradiol (EE), a major constituent of many oral contraceptives, inactivated the testosterone 6 beta-hydroxylation activity of purified P450 3A4 reconstituted with phospholipid and NADPH-cytochrome P450 reductase in a mechanism-based manner. The inactivation of P450 3A4 followed pseudo first order kinetics and was dependent on NADPH. The values for the K(I) and k(inact) were 18 microM and 0.04 min(-1), respectively, and the t(1/2) was 16 min. Incubation of 50 microM EE with P450 3A4 at 37 degrees C for 30 min resulted in a 67% loss of testosterone 6 beta-hydroxylation activity accompanied by a 35% loss of the spectral absorbance of the native protein at 415 nm and a 70% loss of the spectrally detectable P450-CO complex. The inactivation of P450 3A4 by EE was irreversible. Testosterone, an alternate substrate, was able to protect P450 3A4 from EE-dependent inactivation. The partition ratio was approximately 50. The stoichiometry of binding was approximately 1.3 nmol of an EE metabolite bound per nmol of P450 3A4 inactivated. SDS-polyacrylamide gel electrophoresis analysis demonstrated that [(3)H]EE was irreversibly bound to the P450 3A4 apoprotein. After extensive dialysis of the [(3)H]EE inactivated samples, high-pressure liquid chromatography (HPLC) analysis demonstrated that the inactivation resulting from EE metabolism led to the destruction of approximately half the heme with the concomitant generation of modified heme and EE-labeled heme fragments and produced covalently radiolabeled P450 3A4 apoprotein. Electrospray mass spectrometry demonstrated that the fraction corresponding to the major radiolabeled product of EE metabolism has a mass (M - H)(-) of 479 Da. HPLC and gas chromatography-mass spectometry analyses revealed that EE metabolism by P450 3A4 generated one major metabolite, 2-hydroxyethynylestradiol, and at least three additional metabolites. In conclusion, our results demonstrate that EE is an effective mechanism-based inactivator of P450 3A4 and that the mechanism of inactivation involves not only heme destruction, but also the irreversible modification of the apoprotein at the active site.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11907170     DOI: 10.1124/jpet.301.1.160

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

Review 1.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

2.  Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol.

Authors:  Herbert Wiesinger; Matthias Berse; Stefan Klein; Simone Gschwend; Joachim Höchel; Frank S Zollmann; Barbara Schütt
Journal:  Br J Clin Pharmacol       Date:  2015-10-28       Impact factor: 4.335

Review 3.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.

Authors:  Yue-Zhong Shu; Benjamin M Johnson; Tian J Yang
Journal:  AAPS J       Date:  2008-03-13       Impact factor: 4.009

5.  1,2,3-Triazole-heme interactions in cytochrome P450: functionally competent triazole-water-heme complexes.

Authors:  Kip P Conner; Preethi Vennam; Caleb M Woods; Matthew D Krzyaniak; Michael K Bowman; William M Atkins
Journal:  Biochemistry       Date:  2012-07-31       Impact factor: 3.162

6.  Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives.

Authors:  Doodipala Samba Reddy
Journal:  Expert Rev Clin Pharmacol       Date:  2010-03-01       Impact factor: 5.045

7.  Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.

Authors:  Michael Mohutsky; Stephen D Hall
Journal:  Methods Mol Biol       Date:  2021

Review 8.  Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation.

Authors:  Paul R Ortiz de Montellano
Journal:  Drug Metab Rev       Date:  2019-07-07       Impact factor: 4.518

9.  CYP3A4 overexpression enhances apoptosis induced by anticancer agent imidazoacridinone C-1311, but does not change the metabolism of C-1311 in CHO cells.

Authors:  Monika Pawłowska; Ewa Augustin; Zofia Mazerska
Journal:  Acta Pharmacol Sin       Date:  2013-12-02       Impact factor: 6.150

10.  Mechanism-based inactivation of CYP2B1 and its F-helix mutant by two tert-butyl acetylenic compounds: covalent modification of prosthetic heme versus apoprotein.

Authors:  Hsia-Lien Lin; Haoming Zhang; Kathleen R Noon; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2009-08-21       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.